Freenome, Inc.
No SEC Form 4 filings for $FRNM in the last 30 days.
See all $FRNM insider activity →ARK ETFs sold 670,746 shares of Personalised (PSNL) for $10.7M, bought 254,668 shares of Freenome (FRNM) for $3.1M, sold 59,477 shares of CareDx (CDNA) for $4M, and bought 29,416 shares of Scribe Therapeutics (SCTX) for $609K. These trades indicate ARK's strategic portfolio adjustments.
Freenome (FRNM) will release Q3 2026 results on Nov. 10 after market close, followed by a call at 1:30 PM PT. The company develops blood-based cancer detection tests, including SimpleScreen CRC for colorectal cancer.
Freenome updated its SimpleScreen CRC blood test, reporting 80.4% sensitivity at 90% specificity and improved advanced precancerous lesion detection. The company aims for regulatory clearance and increased adoption through Abbott sales.
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning FRNM (Freenome, Inc.). Coverage has skewed bullish: 5 bullish, 1 neutral, and 1 bearish.
Recent FRNM coverage spans market movers, financial news and technology.
Potential upside as a prominent investor adds exposure.
This is a pre-earnings scheduling update that sets the catalyst window for FRNM’s next earnings print and related guidance discussion.
Positive clinical data may lift investor sentiment.
Regulatory approvals provide a clear revenue pathway and enhance the company's market positioning in cancer screening.
FDA clearance provides a clear commercial pathway, likely boosting sales and stock momentum.
AlphAI scores every news story that mentions FRNM with an AI model for sentiment and relevance, and aggregates insider trades from Freenome, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ARK ETFs sold 670,746 shares of Personalised (PSNL) for $10.7M, bought 254,668 shares of Freenome (FRNM) for $3.1M, sold 59,477 shares of CareDx (CDNA) for $4M, and bought 29,416 shares of Scribe Therapeutics (SCTX) for $609K. These trades indicate ARK's strategic portfolio adjustments.
1 min readFreenome (FRNM) will release Q3 2026 results on Nov. 10 after market close, followed by a call at 1:30 PM PT. The company develops blood-based cancer detection tests, including SimpleScreen CRC for colorectal cancer.
1 min readFreenome updated its SimpleScreen CRC blood test, reporting 80.4% sensitivity at 90% specificity and improved advanced precancerous lesion detection. The company aims for regulatory clearance and increased adoption through Abbott sales.
1 min readSeveral biotech stocks reached 52-week highs on September 18, 2026. Vogenx (VOGX) shares surged to $38.41, driven by positive clinical trial results. HeartSciences (HSCS) rose 7% to $5.21, while HeartFlow (HTFL) increased 2% to $52.22. Freenome (FRNM) gained 5% to $17.25, and Halozyme (HALO) hit $112.66 after announcing a $1.3B offering.
4 min readOmniAb (OABI) +13% to $5.43, raising 2026 cash flow guidance to $49M-$53M. Freenome (FRNM) +4% to $16.03 after FDA approvals. Exelixis (EXEL) +$59.11, Q2 profit $212M. LifeStance (LFST) +$13.15, Q2 revenue +26% to $435.4M. Faeth (FTH) +$40.89, Q2 loss $16M.
2 min readAethlon Medical (AEMD) reported a 12% narrower Q1 loss and progress in its Hemopurifier study, with shares up 17.5%. Quoin Pharmaceuticals (QNRX) surged 34% pre-market on positive QRX003 data and a $50M financing. Dogwood Therapeutics (DWTX) gained 12% as its Halneuron trial advances. Freenome (FRNM) rose 7% after FDA Breakthrough Device Designation for its lung cancer test.
3 min readJefferies initiated coverage on Freenome (FRNM) with a 'Buy' rating and $17 price target, citing its cancer detection tests and partnerships. Shares rose 12% to $13.00. Freenome's lead product, SimpleScreen, competes in colorectal cancer testing. The company plans to expand into other cancers, with lung cancer next. Key milestones include FDA approvals and a U.S. launch this fall. Freenome is unprofitable but has $1.3B market cap. Jefferies' target implies 47% upside from $11.56 close.
3 min readInvesting.com reports Cathie Wood’s ARK ETFs published Thursday trades. ARK bought 106,941 shares of Cerebras Systems (CBRS) for about $28.0M and bought Securitize (SECZ) and Perceptive Capital Solutions (FRNM). It sold Shopify (SHOP) 57,045 shares for about $8.6M and sold Palantir (PLTR) for about $7.5M, plus other smaller trades.
3 min readFreenome, Inc. (FRNM) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-99.1 19 ef20078324_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Defined terms included below have the same meaning as terms defined and included elsewhere in the Current Report on Form 8-K (the “Form 8-K”) filed with the Sec
6 min readPerceptive Capital Solutions Corp (PCSC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0002017526 0002017526 2026-07-15 2026-07-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July
2 min read
